logo
  

Pfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In Kids

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Monday that they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization or EUA of a 10-g booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.

The request for EUA of the vaccine in this age group is supported by safety and immunogenicity data from the companies' bivalent Omicron BA.1-adapted vaccine, non-clinical and manufacturing data from the companies' 10-g bivalent Omicron BA.4/BA.5-adapted vaccine, and pre-clinical data from Omicron BA.4/BA.5-adapted vaccine in their decision.

The companies will also submit an application to extend the Omicron BA.4/BA.5-adapted bivalent vaccine marketing authorization to include children ages 5 through 11 years to the European Medicines Agency or EMA in the coming days.

Pfizer and BioNTech have also initiated a Phase 1/2/3 study NCT05543616 (C4591048) to evaluate the safety, tolerability, and immunogenicity of different doses and dosing regimens of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age.

The pediatric study, consistent with regulatory guidance, follows a previous Phase 1/2/3 trial involving these age groups that demonstrated the original Pfizer-BioNTech COVID-19 Vaccine is well-tolerated and offers a high level of protection against COVID-19, measured at a time when the Omicron BA.2 strain was highly prevalent.

The Pfizer-BioNTech COVID-19 Vaccine is based on BioNTech's proprietary mRNA technology. It was developed by both BioNTech and Pfizer.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional... Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton.
Follow RTT